ALKERMES | ALKS - Assets


ALKERMES reported $2.49B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
ALKERMES USD 2.49B 157.48M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Malin Corporation EUR 198.5M 70.1M Dec/2024
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Otsuka Holdings JPY 4.2T 238.02B Dec/2025
Ovoca Bio EUR 1.66M 9.75M Jun/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025